Cargando…

High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer

BACKGROUND: LARGE1 plays a pivotal role in glycosylation of alpha-Dystroglycan (α-DG) and is aberrantly downregulated in cell lines originating from epithelium-derived cancers including lung cancer. However, the expression of LARGE1 and its clinical significance in NSCLC are not clear. MATERIALS AND...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yu, Huang, Shirui, Kuang, Mengjiao, Wang, Huiyan, Xie, Qipeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822230/ https://www.ncbi.nlm.nih.gov/pubmed/33500650 http://dx.doi.org/10.2147/PGPM.S271516

Ejemplares similares

The not so small role of adjuvant chemotherapy in resected non-small cell lung cancer
por: Almquist, Daniel R., et al.
Publicado: (2021)

Adjuvant chemotherapy can benefit the survival of stage I lung adenocarcinoma patients with tumour spread through air spaces after resection: Propensity-score matched analysis
por: Xie, Shaonan, et al.
Publicado: (2022)

Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer
por: Van Laar, Ryan K
Publicado: (2012)

Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?
por: Liu, Yutao, et al.
Publicado: (2017)

Radiomics nomogram for prediction disease-free survival and adjuvant chemotherapy benefits in patients with resected stage I lung adenocarcinoma
por: Xie, Dong, et al.
Publicado: (2020)

Epidemiological Characteristics and Drug Resistance Analysis of Cerebrospinal Fluid Microbial Infections in Wenzhou Area
por: Zhou, Teng, et al.
Publicado: (2021)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10
por: Grieve, Stacy, et al.
Publicado: (2020)

Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2018)

Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research
por: Bonomi, Maria, et al.
Publicado: (2011)

Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer
por: Lee, Yu Kyung, et al.
Publicado: (2018)

Impact of age on adjuvant chemotherapy after radical resection in patients with non–small cell lung cancer
por: Zhai, Xiaoyu, et al.
Publicado: (2016)

Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer
por: Kuang, Peng-Peng, et al.
Publicado: (2021)

Adjuvant chemotherapy of non-small-cell lung cancer
por: Douillard, J.Y.
Publicado: (2013)

Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
por: Pirker, Robert
Publicado: (2012)

Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer
por: Yan, Shi, et al.
Publicado: (2010)

Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of ACTN4 According to Evaluation of Metastatic Ability
por: Tozuka, Takehiro, et al.
Publicado: (2022)

Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer
por: Wang, Xiangxue, et al.
Publicado: (2021)

Development and validation of a polygenic hazard score to predict prognosis and adjuvant chemotherapy benefit in early-stage non-small cell lung cancer
por: Li, Dan-Hua, et al.
Publicado: (2022)

Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study
por: Zaanan, Aziz, et al.
Publicado: (2023)

The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study
por: Leiter, Amanda, et al.
Publicado: (2022)

Randomised study of adjuvant chemotherapy for completely resected p-stage I–IIIA non-small cell lung cancer
por: Nakagawa, K, et al.
Publicado: (2006)

A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma
por: Ma, Xiaoling, et al.
Publicado: (2022)

Expression of Serum Cytokines Profile in Neonatal Sepsis
por: Chen, Suipeng, et al.
Publicado: (2022)

miR-190 promotes malignant transformation and progression of human urothelial cells through CDKN1B/p27 inhibition
por: Huang, Shirui, et al.
Publicado: (2021)

Benefit of adjuvant chemotherapy for patients with stage IB non-small cell lung cancer: a systematic review and meta-analysis
por: Wang, Xiaofan, et al.
Publicado: (2021)

Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2019)

Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer
por: Patel, Manali I., et al.
Publicado: (2011)

Adjuvant Chemotherapy Following Surgical Resection Improves Survival in Patients With Early Stage Small Cell Lung Cancer
por: Yao, Yuanshan, et al.
Publicado: (2019)

Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature
por: Desage, Anne-Laure, et al.
Publicado: (2021)

Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?
por: Lee, Kuan-Yu, et al.
Publicado: (2023)

Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer
por: Péchoux, Cecile Le, et al.
Publicado: (2013)

Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study
por: Pu, Ning, et al.
Publicado: (2023)

Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy
por: Schenone, Aaron D, et al.
Publicado: (2014)

Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study
por: Takashima, Shinogu, et al.
Publicado: (2020)

Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
por: Liang, Sheng‐Kai, et al.
Publicado: (2023)

Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse
por: Lim, Jeong Uk
Publicado: (2023)

Update of Adjuvant Chemotherapy for Resected Gastric Cancer
por: Oh, Sang Cheul
Publicado: (2012)

Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy
por: Bergot, Emmanuel, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8a9asls5bmmcodv4p6vcr444o5